{
  "meta": {
    "title": "Ischemic_Heart_Diseases_Part_2",
    "url": "https://brainandscalpel.vercel.app/ischemic-heart-diseases-part-2-eafd153d.html",
    "scrapedAt": "2025-11-30T11:13:07.994Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Discharge home with referral to the outpatients department</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Low molecular weight heparin</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Thrombolysis with tissue plasminogen activator</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Urgent coronary angiography</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 74-year-old diabetic man is admitted to the ER with a 40-minute history of central, crushing chest pain. The pain eases after an hour with bed rest, oxygen and morphine. ECG shows mild anterior ST flattening. The troponin T level is slightly raised.<br>What would be the optimal management of the underlying cause of his chest pain besides the usual medical measures?</span></p>",
      "unique_key": "DT1280070",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280070,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient falls into the high-risk category of acute coronary syndrome.</p>\r\n<p><strong>Acute coronary syndrome</strong> is a medical emergency, which, if untreated, will progress to myocardial infarction in over 10% of cases.</p>\r\n<p><strong>High-risk patients may have one or more of the following features:</strong></p>\r\n<ul>\r\n<li>Prolonged, ongoing (&gt; 20 min) rest pain</li>\r\n<li>Pulmonary oedema or angina with hypotension</li>\r\n<li>Rest angina with dynamic ST changes &gt; 1 mm</li>\r\n<li>Raised troponin (I and T)</li>\r\n<li>Age &gt; 70 years</li>\r\n<li>Diabetes mellitus</li>\r\n</ul>\r\n<p>Those at high risk should proceed promptly to angiography to proceed to revascularisation, where appropriate, during that admission.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Discharge home with outpatient referral (Option A): </strong>Inadequate for high-risk ACS and delays definitive diagnosis and revascularisation, increasing morbidity and mortality.</p>\r\n<p><strong>Low molecular weight heparin (Option B): </strong>Appropriate anticoagulation but insufficient alone; invasive assessment is required to guide revascularisation strategy.</p>\r\n<p><strong>Thrombolysis with tPA (Option C): </strong>Not indicated in non-ST-elevation ACS where the vessel is not completely occluded; increases bleeding risk without proven benefit in NSTE-ACS.</p>",
      "correct_choice_id": 4,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Blood pressure 160/110 mmHg</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">History of likely ischaemic stroke within the past month</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">ST-segment elevation in ECG</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Previous aspirin therapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old man with chest pain of 1-hour duration is diagnosed as having an acute myocardial infarction. Which of the following features, if present, would most contraindicate thrombolytic therapy?</span></p>",
      "unique_key": "DT1280071",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280071,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>There is an approximate 1% risk of stroke and a 0.7% risk of major haemorrhage associated with the use of thrombolysis.</p>\n<p>Recombinant tissue plasminogen activator (TPA) is connected with a lower rate of intracranial haemorrhage and hence is the drug of choice for thrombolysis in acute myocardial infarction of less than 12 hours' duration.</p>\n<p><strong>Absolute contraindications for thrombolytic therapy</strong></p>\n<ul>\n<li>Aortic dissection</li>\n<li>Previous cerebral hemorrhage</li>\n<li>Known history of cerebral aneurysm or arteriovenous malformation</li>\n<li>Known intracranial neoplasm</li>\n<li>Recent (within the past 6 months) thromboembolic stroke</li>\n<li>Active internal bleeding (excluding menstruation)</li>\n</ul>",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">It inhibits cyclo-oxygenase</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">It is a glycoprotein IIb/IIIa inhibitor</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">It is a hydroxymethyl coenzyme A inhibitor</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">It is an ADP receptor antagonist</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is true regarding the action of clopidogrel?</span></p>",
      "unique_key": "DT1280072",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280072,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Clopidogrel</strong> prevents platelet aggregation through antagonism of the <strong>adenosine diphosphate (ADP) receptor.</strong></li>\n<li>It has been shown to reduce mortality from stroke and <strong>ischaemic heart disease (IHD)</strong> in primary prevention studies.</li>\n<li><strong>Vorapaxar</strong>is an anti-platelet agent that reduces platelet aggregation through reversible antagonism of Protease Activated Receptor-1 (PAR 1), also known as thrombin receptor.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>It inhibits cyclo-oxygenase (Option A):</strong> False, as this describes aspirin's mechanism, not clopidogrel's.</p>\n<p><strong>It is a glycoprotein IIb/IIIa inhibitor (Option B): </strong>False, agents like abciximab and eptifibatide have this action; clopidogrel acts upstream at the ADP receptor.</p>\n<p><strong>It is a hydroxymethyl coenzyme A inhibitor (Option C): </strong>False, as this describes statins (e.g., atorvastatin), not clopidogrel.</p>",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Age of patient</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Premature withdrawal of antiplatelet therapy</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Failing to adhere to cardiac rehabilitation program</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Duration of procedure</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old man with angina has a percutaneous coronary intervention with insertion of a drug-eluting stent. What is the single most important risk factor for stent thrombosis?</span></p>",
      "unique_key": "DT1280074",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280074,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>PCI:</strong> Stent thrombosis - withdrawal of antiplatelets biggest risk factor</p>\n<p><strong>Diabetes mellitus</strong> is a risk factor for restenosis rather than stent thrombosis.</p>\n<p><strong>Percutaneous coronary intervention</strong></p>\n<p>Percutaneous coronary intervention (PCI) is a technique used to restore myocardial perfusion in patients with ischaemic heart disease, both in patients with stable angina and acute coronary syndromes. Stents are implanted in around 95% of patients undergoing PCI.</p>\n<p><strong>Complications following stent placement</strong></p>\n<ol>\n<li>Stent thrombosis: due to platelet aggregation as above. Occurs in 1-2% of patients, most commonly in the first month. Usually presents with acute myocardial infarction.</li>\n<li>Restenosis: due to excessive tissue proliferation around the stent. Occurs in around 5-20% of patients, most commonly in the first 3-6 months. Usually presents with the recurrence of angina symptoms. Risk factors include diabetes, renal impairment and stents in venous bypass grafts.</li>\n</ol>\n<p><strong>Types of stents</strong></p>\n<ul>\n<li>Bare-metal stent (BMS)</li>\n<li>Drug-eluting stents (DES): Stent coated with paclitaxel or rapamycin which inhibit local tissue growth. Whilst this reduces restenosis rates, the stent thrombosis rates are increased as the process of stent endothelialisation is slowed.</li>\n</ul>\n<p>Aspirin should be continued indefinitely. The length of clopidogrel treatment depends on the type of stent, reason for insertion and consultant preference.</p>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary embolism</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Cardiogenic shock</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Papillary muscle rupture</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Ventricular fibrillation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old man with no significant past medical history is admitted to the Emergency Department. His ECG is consistent with an anterior myocardial infarction. Unfortunately, he develops cardiac arrest shortly after arriving in the department. What is the most common cause of death in patients following a myocardial infarction?</span></p>",
      "unique_key": "DT1280075",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280075,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Ventricular fibrillation</strong> is the <strong>most common cause of death following a MI</strong>. Other common arrhythmias including ventricular tachycardia.</p>\r\n<p><strong>Myocardial infarction: Complications</strong></p>\r\n<p>Patients are at risk of a number of immediate, early and late complications following a myocardial infarction (MI).</p>\r\n<ol>\r\n<li><strong>Cardiac arrest</strong>: Most often from ventricular fibrillation; managed per ALS protocol with immediate defibrillation.</li>\r\n<li><strong>Cardiogenic shock</strong>: Results when extensive myocardial loss (or mechanical failure such as free-wall rupture) reduces LV output; may require inotropes and/or intra-aortic balloon pump.</li>\r\n<li><strong>Chronic heart failure</strong>: Persistent LV dysfunction after the acute phase leads to ongoing systolic or diastolic failure.</li>\r\n<li><strong>Tachyarrhythmias</strong>: Ventricular fibrillation, ventricular tachycardia.</li>\r\n<li><strong>Bradyarrhythmias</strong>: AV block is common after inferior MI</li>\r\n<li><strong>Pericarditis</strong>: Occurs in ~10% within 48 hrs of transmural MI; presents with pleuritic chest pain, friction rub, and possible effusion.</li>\r\n<li><strong>Dressler's syndrome:</strong> Autoimmune pericarditis 2-6 weeks post-MI, with fever, pleuritic pain, effusion, and elevated ESR; treated with NSAIDs.</li>\r\n<li><strong>Left ventricular aneurysm: </strong>Myocardial weakening leads to aneurysm formation, persistent ST elevation, LV failure, and thrombus risk requiring anticoagulation.</li>\r\n<li><strong>Left ventricular free wall rupture</strong>: Occurs in ~3% around days 7-14; causes tamponade (raised JVP, pulsus paradoxus, muffled sounds) and demands emergent pericardiocentesis/surgery.</li>\r\n<li><strong>Ventricular septal defect</strong>: Septal rupture in ~1-2% within first week; acute heart failure with pansystolic murmur-diagnosed by echo and managed surgically.</li>\r\n<li><strong>Acute mitral regurgitation</strong>: Often after inferoposterior MI due to papillary muscle dysfunction or rupture; presents with pansystolic murmur and pulmonary edema. Treated initially with vasodilators but usually needs surgical repair.</li>\r\n</ol>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">More common in women</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Classically cause transmural ischemia compared to subendocardial ischemia in angina pectoris</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Associated with rest pain and ST segment elevation on ECG</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta blockers and nitrates are the preferred treatment</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not true regarding management of vasospastic (Prinzmetal) angina?</span></p>",
      "unique_key": "DT1280076",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280076,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Transient coronary artery spasm </strong>is the basis for <strong>Prinzmetal (vasospastic) angina </strong>which can result in <strong>transient ST elevation and spasm which is evident on coronary angiography.</strong></li>\n<li>Epidemiology shows a <strong>female predominance</strong> in the fourth to fifth decades. <strong>(Option A)</strong></li>\n<li>Spasm fully occludes a coronary segment, causing epicardial and endocardial injury. <strong>(Option B)</strong></li>\n<li>Vasospasm typically occurs at rest and produces transient ST elevations that normalize when spasm resolves. <strong>(Option C)</strong></li>\n<li><strong>Nitrates and calcium channel blockers</strong> are the preferred treatment options for vasospastic angina.</li>\n<li><strong>Beta blockers are not used</strong> as unopposed alpha receptor action of catecholamines would <strong>worsen coronary vasoconstriction.</strong></li>\n</ul>",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Bendrofluazide</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Isosorbide Mononitrate</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Lisinopril</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48 year old male is referred to with impotence. He has a history of angina, hypertension and type 2 diabetes. Which one of the following drugs that he takes would present a contraindication towards him receiving Sildenafil?</span></p>",
      "unique_key": "DT1280077",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280077,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Sildenafil is a phosphodiesterase-5 inhibitor used in management of erectile dysfunction. Like nitrates (e.g. isosorbide mononitrate) it also increases the release of NO resulting in hypotension.</li>\n<li>There is a significant <strong>risk of hypotension when sildenafil is used with nitrates</strong>.</li>\n<li>There should be at least 24 hours gap between administration of nitrates and short acting PDE5 inhibitors like sildenafil and 48 hours between the use of long acting Tadalafil.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aspirin (Option A): </strong>An antiplatelet agent without hemodynamic interaction with PDE5 inhibitors.</p>\n<p><strong>Bendrofluazide (Option B): </strong>A thiazide diuretic that does not potentiate sildenafil's vasodilatory effects.</p>\n<p><strong>Lisinopril (Option D): </strong>An ACE inhibitor; while it lowers blood pressure, it does not have the acute synergy with PDE5 inhibitors seen with nitrates.</p>",
      "correct_choice_id": 63,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Palmar xanthomas</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Autosomal recessive inheritance</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased LDL concentrations</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypertriglyceridemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55 year old man with angina has familial hypercholesterolaemia. His father and uncle both have coronary heart disease.<br>Which one of the following is a typical feature for the condition?</span></p>",
      "unique_key": "DT1280078",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280078,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Familial hypercholesterolaemia (FH) </strong>is an autosomal dominant condition most commonly due to inactivating mutation in the LDL receptor gene.</li>\n<li>There is increased LDL concentration due to reduced numbers of LDL receptors.</li>\n<li>Elevated LDL drives accelerated atherosclerosis, explaining the early onset coronary disease in affected family members.</li>\n<li>Clinical severity correlates with LDL concentration; untreated heterozygotes may have LDL &gt; 190 mg/dL, while homozygotes can exceed 500 mg/dL.</li>\n<li>Hypertriglyceridaemia does not usually occur and HDL concentrations are usually decreased.</li>\n</ul>\n<p><strong>Clinical Features of Familial Hypercholesterolemia </strong></p>\n<ul>\n<li><strong>Tendon xanthomas</strong> (Achilles, extensor tendons of hands)</li>\n<li><strong>Tuberous xanthomas</strong> over pressure areas (elbows, knees)</li>\n<li><strong>Corneal arcus</strong> appearing before age 45</li>\n<li><strong>Xanthelasma palpebrarum</strong> (eyelid plaques)</li>\n<li><strong>Premature atherosclerotic cardiovascular disease</strong>\n<ul>\n<li>Men &lt; 55 years, women &lt; 65 years</li>\n</ul>\n</li>\n<li><strong>Markedly elevated LDL cholesterol</strong>\n<ul>\n<li>Heterozygotes: &ge; 190 mg/dL</li>\n<li>Homozygotes: often &gt; 500 mg/dL</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Palmar xanthomas (Option A):</strong> Characteristic of dysbetalipoproteinemia, not FH.</p>\n<p><strong>Autosomal recessive inheritance (Option B):</strong> FH follows an autosomal dominant pattern; homozygotes are simply more severely affected.</p>\n<p><strong>Hypertriglyceridemia (Option D):</strong> Triglyceride levels are typically normal or mildly elevated in FH; the hallmark is isolated LDL elevation.</p>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Urokinase</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Streptokinase</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Alteplase</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenecteplase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following fibrinolytic agents has the highest clot specificity?</span></p>",
      "unique_key": "DT1280079",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280079,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Fibrin selective plasminogen activators include Alteplase, Tenecteplase and Reteplase.</li>\n<li>Tenecteplase has highest clot specificity, while Streptokinase has least fibrin specificity.</li>\n<li>Streptokinase is given at a dose of 1.5 million units IV infusion given over 1 hour while Tenecteplase is administered as a single bolus dose.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Urokinase (Option A):</strong> Non-selective activation of plasminogen leads to systemic fibrinolysis and increased bleeding risk.</p>\n<p><strong>Streptokinase (Option B): </strong>Least fibrin specificity; promotes widespread fibrinogen degradation.</p>\n<p><strong>Alteplase (Option C): </strong>Fibrin-selective but less clot-specific than tenecteplase and requires a 90-minute infusion.</p>",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">History of hemorrhagic stroke</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Pregnancy</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Cerebrovascular accident in the preceding one year</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Suspected aortic dissection</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not an absolute contraindication for fibrinolytic therapy in a patient with acute MI?</span></p>",
      "unique_key": "DT1280080",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280080,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Pregnancy is classified as a relative rather than absolute contraindication</strong> for fibrinolysis. The decision balances maternal benefit against fetal risk, and therapy may proceed in life-threatening MI under specialist guidance.</p>\n<p><strong>Absolute contraindications for use of fibrinolytic therapy in MI</strong></p>\n<ul>\n<li>History of hemorrhagic stroke at any time</li>\n<li>Cerebrovascular events in the preceding year</li>\n<li>Systolic blood pressure &gt; 180 mmHg or diastolic BP &gt; 110 mmHg at any time during presentation</li>\n<li>Suspicion of aortic dissection</li>\n<li>Active internal bleeding excluding menstrual bleed.</li>\n</ul>\n<p><strong>Relative contraindications</strong></p>\n<ul>\n<li>Current use of anti-coagulants</li>\n<li>Pregnancy</li>\n<li>Recent (&lt; 2 weeks) invasive surgical procedure</li>\n<li>Prolonged (&gt; 10 min) CPR</li>\n<li>Active peptic ulcer disease</li>\n<li>History of severe hypertension that is controlled at present</li>\n</ul>",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Aortic regurgitation</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Cardiac tamponade</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary regurgitation</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Right heart failure</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Angina due to an imbalance between O2 supply and demand without atherosclerosis would most likely be seen in which of the following circumstances?</span></p>",
      "unique_key": "DT1280081",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280081,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Chronic aortic regurgitation leads to left <strong>ventricular dilation and hypertrophy, </strong>raising wall stress and oxygen demand.</li>\n<li><strong>Regurgitant flow shortens diastolic filling time</strong>, reducing coronary perfusion when the myocardium needs it most.</li>\n<li>This creates<strong> a supply-demand mismatch and angina</strong> despite normal coronary arteries.</li>\n<li>Non-atherosclerotic angina would be associated with conditions such as thyrotoxicosis, aortic regurgitation, aortic stenosis, hypertrophic cardiomyopathy and anaemia.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Cardiac tamponade (Option B): </strong>Impairs chamber filling but does not typically reduce coronary perfusion enough to cause angina until late tamponade.</p>\n<p><strong>Pulmonary regurgitation (Option C): </strong>Affects right ventricular volume without significantly altering left ventricular oxygen balance.</p>\n<p><strong>Right heart failure (Option D): </strong>Impairs systemic return and right ventricular output but does not directly create left ventricular ischemia.</p>",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Allergic reaction to thrombolysis</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin allergy</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholesterol emboli</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Peripheral vascular disease</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\"><p>A 62-year-old male is admitted with an inferior myocardial infarction and receives thrombolysis with streptokinase, aspirin, atenolol, simvastatin and ramipril. His ECG shows good ST-segment resolution. The following day, he develops some pain in the legs and a dusky discolouration of the lower limbs. On closer examination, there is a diffuse petechial rash over the lower legs, particularly the feet, but all peripheral pulses are palpable. Investigations reveal:<br /><br />Hemoglobin 13.3 g/dl (12-16)<br />Platelets 145 x 10^9/L (140-450)<br />White cell count 12.1 x 10^9/L (4-10)<br />Neutrophils 6.5 x 10^9/L (2-7)<br />Lymphocytes 3.5 x 10^9/L (1-3.5) <br />Eosinophils 1.2 x 10^9/L (0.3-06)<br />Which of the following is the most likely cause for his current problems?</p></span></p>",
      "unique_key": "DT1280082",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280082,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has <strong>acute MI and one day after thrombolysis</strong> develops this <strong>petechial rash in the lower limbs</strong> with raised white cell count - <strong>marked</strong> <strong>eosinophilia</strong>. This is the classical picture of <strong>cholesterol embolism syndrome, </strong>where a cholesterol crystal breaks off from an atherosclerotic plaque in an artery and lodges in smaller arteries elsewhere.</li>\n<li>The most commonly involved organs include the <strong>kidneys, skin, GI tract and brain.</strong></li>\n<li><strong>Renal involvement </strong>would lead to <strong>eosinophiluria and AKI, </strong>while embolism to the <strong>legs can cause a mottled appearance and purple discolouration of the toes</strong>, small infarcts, areas of gangrene, and a marbled pattern on the skin known as <strong>livedo reticularis.</strong></li>\n<li>A biopsy of the affected organ would confirm the diagnosis.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250920e2e694ad-ced8-4fd7-bf4e-2bb1618d3533.png\">\n<p>Livedo reticularis</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Allergic reaction to thrombolysis (Option A): </strong>Would feature urticaria, hypotension, bronchospasm, and eosinophilia but not livedoid skin changes with palpable pulses.</p>\n<p><strong>Aspirin allergy (Option B): </strong>Typically causes bronchospasm or urticaria without petechial rash or eosinophilia.</p>\n<p><strong>Peripheral vascular disease (Option D): </strong>Leads to diminished pulses and chronic claudication, not acute livedoid rash or eosinophilia.</p>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">It is a parenteral direct thrombin inhibitor</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">The Antidote for bivalirudin toxicity is protamine</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">No dose adjustments required in renal failure patients</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">It is contraindicated in heparin-induced thrombocytopenia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old male patient presented with myocardial infarction and was planned for urgent percutaneous coronary intervention. Bivalirudin was used as an anticoagulant in this patient. Which of the following statements is true about the drug used?</span></p>",
      "unique_key": "DT1280083",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280083,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Bivalirudin is a synthetic polypeptide that can be used in patients undergoing PCI or coronary bypass surgery for STEMI and NSTEMI as an anticoagulant along with antiplatelet drugs like aspirin.</li>\n<li><strong>Bivalirudin is a parenteral direct thrombin inhibitor.</strong></li>\n<li><strong>Lepirudin </strong>and <strong>argatroban</strong>are licensed for the <strong>treatment of HIT</strong>, whereas <strong>bivalirudin </strong>is approved as an <strong>alternative to heparin in patients undergoing PCI</strong>, including those with HIT <strong>(Option D ruled out)</strong></li>\n<li><strong>Protamine is the antidote for heparin</strong>, not bivalirudin. <strong>(Option B ruled out)</strong></li>\n<li>Bivalirudin is eliminated by the kidneys, so dose adjustments may be needed in patients with severe renal impairment. <strong>(Option C ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Eptifibatide</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Abciximab</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Tirofiban</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Fondaparinux</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The platelet-bound half-life is longest for which of the following Glycoprotein IIb/IIIa Antagonists?</span></p>",
      "unique_key": "DT1280084",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280084,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Abciximab</strong> has the longest platelet-bound half-life among the <strong>Glycoprotein IIb/IIIa </strong>antagonists.</p>\n<p><strong>Abciximab is a monoclonal antibody fragment</strong> that binds irreversibly to the <strong>platelet GPIIb/IIIa receptor</strong>, resulting in a <strong>platelet-bound half-life of up to 10 days </strong>despite a short plasma half-life.</p>\n<p>Its prolonged receptor occupancy provides <strong>potent and sustained inhibition of platelet aggregation</strong>, which is <strong>useful during high-risk PCI procedures.</strong></p>\n<p>Platelet function recovery after abciximab requires new receptor synthesis, explaining the extended duration of action compared to other agents.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509204e689e1d-ce1a-4b2a-a26b-e968b8897636.png\">",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Myocardial Infarction related to stent thrombosis</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Myocardial Infarction related to Coronary Artery Bypass Grafting</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Myocardial Infarction resulting in death when biomarker values are unavailable</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Myocardial Infarction related to Percutaneous Coronary Intervention</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following explains type 5 MI according to the Third Universal Myocardial Infarction Classification?</span></p>",
      "unique_key": "DT1280085",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280085,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Type 5 MI </strong>is defined as myocardial infarction occurring in the <strong>setting of coronary artery bypass graft surgery</strong>, identified by <strong>new Q waves</strong> or <strong>imaging evidence of new loss of viable myocardium in a distribution consistent with a bypass graft.</strong></p>\n<p><strong>Third Universal Myocardial Infarction (MI) Classification </strong></p>\n<p><strong>Type 1: Spontaneous Myocardial Infarction</strong></p>\n<ul>\n<li>Spontaneous MI related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries.</li>\n</ul>\n<p><strong>Type 2: Myocardial Infarction Secondary to Ischemic Imbalance</strong></p>\n<ul>\n<li>In cases of myocardial injury with necrosis in which a condition other than CAD contributes to an imbalance between myocardial oxygen supply and/or demand (e.g., coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachy/bradyarrhythmias, anaemia, respiratory failure, hypotension, hypertension &plusmn; left ventricular hypertrophy).</li>\n</ul>\n<p><strong>Type 3: Myocardial Infarction resulting in death when biomarker values are unavailable (Option C) </strong></p>\n<ul>\n<li>Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic changes on the ECG or new LBBB, but death occurred before blood samples could be obtained.</li>\n</ul>\n<p><strong>Type 4a: Myocardial Infarction Related to Percutaneous Coronary Intervention</strong></p>\n<p><strong>Type 4b: Myocardial Infarction Related to Stent Thrombosis</strong></p>\n<p><strong>Type 5: Myocardial Infarction Related to Coronary Artery Bypass Grafting</strong></p>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Stunning is a state of depressed myocardial function due to chronic hypoperfusion</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Stunning can be global or regional</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Myocardial stunning affects both systolic and diastolic function</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Oxygen free radicals and excess intracellular calcium likely contribute to stunning</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements regarding myocardial stunning is incorrect?</span></p>",
      "unique_key": "DT1280086",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280086,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Myocardial stunning </strong>represents prolonged <strong>myocardial dysfunction</strong> that follows a <strong>brief episode</strong> of <strong>severe ischemia</strong>, with gradual return of contractile activity.</p>\n<p>Conversely, <strong>Myocardial hibernation</strong> is the term applied to <strong>myocardial dysfunction</strong> resulting from <strong>chronic hypoperfusion</strong>.</p>\n<p><strong>Myocardial stunning affects both systolic and diastolic function</strong> and may occur in<strong> globally as well as regionally ischemic myocardium</strong>.<strong> (Option B &amp; C)</strong></p>\n<p>Clinically, stunning is most frequently seen in patients recovering from ischemic arrest during cardiopulmonary bypass.</p>\n<p><strong>Reperfusion injury </strong>mediated by<strong> oxygen free radicals and intracellular calcium overload</strong> underlies the reversible contractile depression characteristic of stunning. <strong> (Option D)</strong></p>\n<p><strong>3 mechanisms of myocardial stunning:</strong></p>\n<ol>\n<li>Generation of oxygen-derived free radicals,</li>\n<li>Calcium overload, and</li>\n<li>Reduced sensitivity of myofilaments to calcium.</li>\n</ol>",
      "correct_choice_id": 151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperglycemia</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Elevated serum triglycerides</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Abdominal obesity</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum low-density lipoprotein >140 mg/dL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a component of the atherogenic 'metabolic syndrome'?</span></p>",
      "unique_key": "DT1280087",
      "question_audio": null,
      "question_video": null,
      "map_id": 1280087,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Metabolic syndrome</strong> is defined by <strong>insulin resistance</strong> and a specific cluster of risk factors like <strong>central obesity, hypertriglyceridemia, low HDL, hypertension, and elevated fasting glucose</strong>, but it does <strong>not include elevated LDL cholesterol</strong> in its diagnostic criteria.</p>\r\n<p><strong>LDL cholesterol</strong>, while an important atherogenic lipoprotein, is managed separately based on overall cardiovascular risk rather than as part of the metabolic'syndrome definition.</p>\r\n<p>Recognising the distinction prevents over-attributing risk to metabolic syndrome when elevated LDL requires targeted statin therapy according to separate guidelines.</p>\r\n<p>The <strong>NCEP ATP III </strong>criteria provide a standardised set of clinical and laboratory thresholds to diagnose metabolic syndrome and guide cardiovascular risk reduction.</p>\r\n<p><strong>Diagnosis requires the presence of three or more of the following five criteria.</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250920cb3733ce-7402-4bfa-ae76-1bf41f6f5511.png\">",
      "correct_choice_id": 164,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}